# A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

> **NCT05252533** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 31 (actual)

## Conditions studied

- Juvenile Psoriatic Arthritis
- Psoriasis
- Arthritis, Juvenile

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT05252533
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-24
- **Primary completion:** 2024-01-26
- **Final completion:** 2024-01-26
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05252533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05252533, "A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05252533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*